Life360 Bulls Like User, Subscription Momentum -- Market Talk
Dow Jones2026/08/12 03:480348 GMT - Life360's bulls at Morgan Stanley reiterate their overweight recommendation on the tracking-app developer despite it needing a strong second half to achieve its earnings guidance. Analysts at the investment bank tell clients in a note that early third-quarter momentum in user growth looks promising. They say that the quality of the users being added remains strong, which is positive for earnings given the dual-listed company's ability to persuade users of its free product to upgrade to paid subscriptions. This improved conversion trend continued in the June quarter, they add. MS trims its target price on Life360's U.S.-listed stock 1.6% to US$65.20, and on its ASX-listed stock by 1.6% to 31.50 Australian dollars. The latter is down 2.9% at A$23.06. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
August 11, 2026 23:48 ET (03:48 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Crypto prices
More
